A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Inclusion Criteria: * Willing and able to provide written informed consent for the trial * ≥ 18 years of age * Histologically- or cytologically- confirmed locally advanced or metastatic WDNET * SSA therapy is recommended by physician for disease management, and has not yet begun * ECOG performance status of 0, 1, or 2 Exclusion Criteria: * Currently participating in a study of an investigational agent * Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent \*Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study * No concurrent chemotherapy or targeted small molecule therapy * If received major surgery, not recovered adequately from the toxicity and/or complications from the intervention prior to starting the study * Known additional malignancy that is progressing or requires active treatment * Active infection requiring systemic therapy * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial